PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment
To evaluate the safety and effectiveness of NeuVax (the study drug), in preventing the recurrence of node-positive, early stage breast cancer with low to intermediate HER2 expression.
Early stage breast cancer with low to intermediate HER2 expression
18 - 100
Healthy Volunteers Needed
Duration of Participation
36 months of study drug doses and up to 10 years for follow-up
Deirdre Nauman, RN (503-494-3078)